PATHOMIQ, Inc.

About

PATHOMIQ develops an AI platform that integrates morphology and genomics from tissue images to predict cancer treatment response and identify molecular biomarkers. The platform analyzes H&E-stained slides to predict outcomes, genotypes, and therapy response for prostate and breast cancers, serving pathology labs, hospitals, cancer centers, and biopharma companies. The company is based in Cupertino, California.

Product

Value proposition

AI-powered interpretable multiomics platform for precision pathology and predictive testing to personalize cancer treatment and guide biomarker discovery

Target customers

pathology labs, hospitals, cancer centers, biopharma (oncology)

Founders

• Parag Jain — Co-Founder and Strategic Advisor
• Wei Huang — Co-Founder and Head of Pathology
• Hirak Basu — Co-Founder and Molecular Scientist
• Shivaani Kummar — Co-Founder
• Rajat Roy — CEO and Co-Founder

Categories

Products

Key features

Technologies

Integrations

Target conditions

Care settings

Investors

News

• Our Team – PATHOMIQ · 2026-03-14T00:00:00.000Z
• Myriad Genetics Partners with PATHOMIQ to add Artificial · 2025-02-24T08:30:00.000Z
• Independent Study Validates PathomIQ AI Digital Pathology Platform for Prostate Cancer Prognosis | 360Dx · 2025-07-07T14:19:36.000Z
• Haynes Boone Guides PATHOMIQ in AI Diagnostics Deal with Myriad Genetics to Transform Cancer Care | News | Haynes Boone · 2025-02-27T23:35:52.000Z
• Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio - BioSpace · 2025-02-25T07:30:36.000Z
• Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer... · 2026-05-26T00:00:00.000Z

Browse related software

• Clinic software in CA
• Clinic software in Cupertino
• Precision Medicine software
• Health AI software
• Oncology software
• All clinic software companies A–Z